Journal de l'épilepsie

Preliminary Findings: Impact of a Single OnabotulinumtoxinA Therapy Session on Sleep Quality and Psychological Measures in Chronic Migraine Patients

Abstract

Paolo Lupica

This study investigates the immediate effects of a single session of OnabotulinumtoxinA therapy on sleep quality and psychological measures in patients suffering from chronic migraine. Chronic migraine is a debilitating condition characterized by frequent and severe headache attacks, often leading to disrupted sleep patterns and adverse psychological well-being. While OnabotulinumtoxinA has shown efficacy in reducing migraine frequency and severity, its impact on sleep quality and psychological parameters remains underexplored. In this preliminary study, a cohort of chronic migraine patients received a single OnabotulinumtoxinA therapy session. Sleep quality was assessed using validated sleep questionnaires, and psychological measures, including anxiety and depression levels, were evaluated through standardized psychological assessments. Baseline measures were compared with post-treatment data to determine the immediate impact of OnabotulinumtoxinA on sleep quality and psychological well-being. Preliminary findings indicate a significant improvement in sleep quality within hours of OnabotulinumtoxinA administration, suggesting its potential role in alleviating sleep disturbances associated with chronic migraine. Furthermore, there was a notable reduction in anxiety and depression scores, highlighting the therapeutic potential of OnabotulinumtoxinA in addressing the psychological burden of chronic migraine patients. These preliminary findings suggest that a single OnabotulinumtoxinA therapy session may have a rapid and positive impact on sleep quality and psychological well-being in chronic migraine patients. Further research is warranted to confirm and expand upon these initial observations and explore the long-term effects of OnabotulinumtoxinA therapy on these parameters.